AU2022315058A1 - Compounds and compositions for the treatment of coronaviral related diseases - Google Patents

Compounds and compositions for the treatment of coronaviral related diseases Download PDF

Info

Publication number
AU2022315058A1
AU2022315058A1 AU2022315058A AU2022315058A AU2022315058A1 AU 2022315058 A1 AU2022315058 A1 AU 2022315058A1 AU 2022315058 A AU2022315058 A AU 2022315058A AU 2022315058 A AU2022315058 A AU 2022315058A AU 2022315058 A1 AU2022315058 A1 AU 2022315058A1
Authority
AU
Australia
Prior art keywords
isoquinolin
carbonitrile
oxoimidazolidine
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022315058A
Other languages
English (en)
Inventor
Denghui BAO
Fengfeng GUO
Matthew James HESSE
Viktor HORNAK
Sajan Joseph
Thomas Martin Kirrane Jr.
Haiyao LIN
Bo Liu
Yanan MIAO
Heinz Ernst Moser
Julien Papillon
Yang Qu
Lei Shi
Jun Yuan
Teng ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2022315058A1 publication Critical patent/AU2022315058A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022315058A 2021-07-22 2022-07-20 Compounds and compositions for the treatment of coronaviral related diseases Pending AU2022315058A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163224793P 2021-07-22 2021-07-22
US63/224,793 2021-07-22
US202163289009P 2021-12-13 2021-12-13
US63/289,009 2021-12-13
PCT/IB2022/056712 WO2023002409A1 (en) 2021-07-22 2022-07-20 Compounds and compositions for the treatment of coronaviral related diseases

Publications (1)

Publication Number Publication Date
AU2022315058A1 true AU2022315058A1 (en) 2024-02-08

Family

ID=82742919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022315058A Pending AU2022315058A1 (en) 2021-07-22 2022-07-20 Compounds and compositions for the treatment of coronaviral related diseases

Country Status (11)

Country Link
US (1) US20250092016A1 (https=)
EP (1) EP4373814A1 (https=)
JP (1) JP2024527424A (https=)
KR (1) KR20240038996A (https=)
AU (1) AU2022315058A1 (https=)
CA (1) CA3226758A1 (https=)
MX (1) MX2024000986A (https=)
PY (1) PY2261702A (https=)
TW (1) TW202321210A (https=)
UY (1) UY39863A (https=)
WO (1) WO2023002409A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
JP7624093B2 (ja) 2022-04-08 2025-01-29 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
WO2024031089A1 (en) 2022-08-05 2024-02-08 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
WO2025125695A2 (en) * 2024-12-17 2025-06-19 Medchemica Consultancy Ltd Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1200825B (de) * 1962-01-13 1965-09-16 Hoechst Ag Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen
WO2010149755A1 (en) * 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17

Also Published As

Publication number Publication date
MX2024000986A (es) 2024-02-12
PY2261702A (es) 2023-06-14
TW202321210A (zh) 2023-06-01
KR20240038996A (ko) 2024-03-26
US20250092016A1 (en) 2025-03-20
UY39863A (es) 2023-02-28
EP4373814A1 (en) 2024-05-29
CA3226758A1 (en) 2023-01-26
WO2023002409A1 (en) 2023-01-26
JP2024527424A (ja) 2024-07-24

Similar Documents

Publication Publication Date Title
US20250092016A1 (en) Compounds and compositions for the treatment of coronaviral related diseases
AU2018221812B2 (en) Pyrrolo [1,2-b] pyridazine derivatives
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
JP6388991B2 (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
CN104922128B (zh) 流感病毒复制抑制剂
US10508113B2 (en) Inhibitors of tyrosine kinase 2 mediated signaling
JP7471348B2 (ja) ブルトン型チロシンキナーゼの阻害剤及びその使用方法
TWI594997B (zh) 流感病毒複製之抑制劑
WO2022224223A1 (en) Compounds and compositions for the treatment of coronaviral related diseases
WO2016024185A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
RS58245B1 (sr) Kombinacija derivata pirolo[2,3-d]pirimidina sa jednim ili više dodatnih sredstava kao inhibitor janus kinaza (jak)
CA2917193A1 (en) Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators
IL300289A (en) Compounds, preparations and methods
TWI712598B (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
CN104619702A (zh) Ccr2的稠合环戊基拮抗剂
JP2018525372A (ja) 呼吸器合胞体ウイルス阻害剤
JP2025508323A (ja) Cdk4/6キナーゼの阻害薬
WO2021202796A1 (en) Pyrrolidine-pyrazoles as pyruvate kinase activators
EA050666B1 (ru) Соединения и композиции для лечения заболеваний, связанных с коронавирусной инфекцией
CN117651699A (zh) 用于治疗冠状病毒相关疾病的化合物和组合物
HK40012561B (en) Heteroaryl compounds and their use as mer inhibitors
HK1243063B (zh) 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物
HK1204322B (en) Inhibitors of influenza viruses replication
HK1169326B (en) Inhibitors of influenza viruses replication